TGFB1 and neoplasm: Treatment with a miR-455-3p antagomir could sensitize ESCC cells to cisplatin and reduce the subpopulations of CD90+ and CD271+ (tumor-initiating cells) T-ICs via inactivation of Wnt/β-catenin and TGF-β signaling pathways [123].